← All trials
NCT04652648
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- Nov 15, 2020
- First posted
- Dec 3, 2020
- Last posted
- Dec 3, 2020
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bryn Mawr HospitalLead sponsor
- Sharpe-Strumia Research FoundationCollaborator
- Bryn Mawr HospitalReponsible party - principal investigator
- Bryn Mawr HospitalCollaborator
- Cotswold FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.